Your Health, We Care
Release date: 2024-08-08 16:15:25 Recommended: 120
Capmatinib is an oral kinase inhibitor targeting mutations in the MET gene, primarily for the treatment of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations.
In clinical trials and practical clinical applications, the most common adverse reactions in the patient population with an incidence of more than 20% mainly include but are not limited to the following:
This refers to the appearance of edema in the limbs of the body, especially the ankles, calves or hands. Patients may experience swelling, tightness, and even disruption to daily activities in these areas. Peripheral edema is usually caused by fluid accumulation in the subcutaneous tissue and may be related to drugs affecting fluid balance or the circulatory system.
People may feel strained and depleted breathing, and may need to increase their breathing rate or use special positions to relieve discomfort. Dyspnea may be a manifestation of drug-induced allergic reactions, impaired lung function, or increased burden on the cardiovascular system.
Understanding the specific drug use groups of drugs can help patients reduce avoidable drug risks and better protect patients. According to the drug label, information on the use of capmatinib in special populations includes but is not limited to the following:
For patients in the stage of mild to moderate renal impairment (baseline creatinine clearance [CLcr] between 30 and 89 mL/min), a special adjustment of the dose of capmatinib is not recommended based on current study data. However, this does not mean that these patients can completely ignore the effects of renal function on drug metabolism and excretion, and should be used with caution under close supervision by a physician.
For patients with severe renal impairment (CLcr between 15 and 29 mL/min), no specific studies have been conducted, and the safety and efficacy of capmatinib in this patient population are uncertain. Doctors need to consider the patient's specific situation and weigh the pros and cons before making a decision.
Animal studies have shown that capmatinib can cause fetal malformations. It is necessary to confirm the non-pregnant status of women before treatment, and it is recommended that men and women of childbearing potential use contraception during treatment and for one week after discontinuation.
[Warm tips] Capmatinib must be used under the guidance of a doctor. Patients are not allowed to change the dosage or discontinue the medication without authorization.
